These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16806558)

  • 1. Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans.
    Kagan L; Lapidot N; Afargan M; Kirmayer D; Moor E; Mardor Y; Friedman M; Hoffman A
    J Control Release; 2006 Jul; 113(3):208-15. PubMed ID: 16806558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citric acid prolongs the gastro-retention of a floating dosage form and increases bioavailability of riboflavin in the fasted state.
    Stops F; Fell JT; Collett JH; Martini LG; Sharma HL; Smith AM
    Int J Pharm; 2006 Feb; 308(1-2):14-24. PubMed ID: 16343829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs.
    Klausner EA; Lavy E; Stepensky D; Friedman M; Hoffman A
    Pharm Res; 2002 Oct; 19(10):1516-23. PubMed ID: 12425470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of riboflavin from a gastric retention formulation.
    Ahmed IS; Ayres JW
    Int J Pharm; 2007 Feb; 330(1-2):146-54. PubMed ID: 17034968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of 3D printing technologies and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems.
    Fu J; Yin H; Yu X; Xie C; Jiang H; Jin Y; Sheng F
    Int J Pharm; 2018 Oct; 549(1-2):370-379. PubMed ID: 30107218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of dual controlled release microballoons containing riboflavin and citric acid: in vitro and in vivo evaluation.
    Singh AN; Pathak K
    J Microencapsul; 2011; 28(5):442-54. PubMed ID: 21554157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified-release capsules containing sodium riboflavin 5'-phosphate.
    Buchholcz G; Kelemen A; Pintye-Hódi K
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1632-6. PubMed ID: 24083326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans.
    Sato Y; Kawashima Y; Takeuchi H; Yamamoto H
    Int J Pharm; 2004 May; 275(1-2):97-107. PubMed ID: 15081141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Accordion Pill
    Navon N
    Ther Deliv; 2019 Jul; 10(7):433-442. PubMed ID: 31203723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview on gastroretentive drug delivery systems for improving drug bioavailability.
    Lopes CM; Bettencourt C; Rossi A; Buttini F; Barata P
    Int J Pharm; 2016 Aug; 510(1):144-58. PubMed ID: 27173823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroretentive dosage forms.
    Moës AJ
    Crit Rev Ther Drug Carrier Syst; 1993; 10(2):143-95. PubMed ID: 8370085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites.
    Akiyama Y; Nagahara N; Nara E; Kitano M; Iwasa S; Yamamoto I; Azuma J; Ogawa Y
    J Pharm Pharmacol; 1998 Feb; 50(2):159-66. PubMed ID: 9530983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers.
    Filipowicz A; Wołowiec S
    Int J Pharm; 2011 Apr; 408(1-2):152-6. PubMed ID: 21272625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the gastrointestinal transit and disintegration behavior of floating and sinking acid-resistant capsules using a novel MRI labeling technique.
    Grimm M; Ball K; Scholz E; Schneider F; Sivert A; Benameur H; Kromrey ML; Kühn JP; Weitschies W
    Eur J Pharm Sci; 2019 Mar; 129():163-172. PubMed ID: 30639530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation.
    Chavanpatil M; Jain P; Chaudhari S; Shear R; Vavia P
    Int J Pharm; 2005 Nov; 304(1-2):178-84. PubMed ID: 16198522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cold-set whey protein microgels containing immobilised lipid phases to modulate matrix digestion and release of a water-soluble bioactive.
    Egan T; Jacquier JC; Rosenberg Y; Rosenberg M
    J Microencapsul; 2014; 31(2):184-92. PubMed ID: 23937209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of preparation conditions on the nutrient release properties of alginate-whey protein granular microspheres.
    Chen L; Subirade M
    Eur J Pharm Biopharm; 2007 Mar; 65(3):354-62. PubMed ID: 17150342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
    Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
    Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation strategies for absorption windows.
    Davis SS
    Drug Discov Today; 2005 Feb; 10(4):249-57. PubMed ID: 15708743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
    Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
    J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.